Mutations in either of the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2, are found in 10–15% of patients at the time of AML diagnosis, and can rarely be acquired at the time of relapse [46]. This evidence concerns the gene IDH2 and acute myeloid leukemia.